These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2120617)

  • 1. Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies.
    Langston JW
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 61-6; discussion 67-9. PubMed ID: 2120617
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective therapy for Parkinson's disease.
    Koller WC
    Exp Neurol; 1997 Mar; 144(1):24-8. PubMed ID: 9126147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neuroprotective and neurorestorative therapy in Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S185-93. PubMed ID: 9280687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxicity and neuroprotection in Parkinson's disease.
    Lange KW; Youdim MB; Riederer P
    J Neural Transm Suppl; 1992; 38():27-44. PubMed ID: 1491247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

  • 8. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
    Amato L; Nava L; Rizzo M; Piccoli F
    Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
    [No Abstract]   [Full Text] [Related]  

  • 9. Is selegiline neuroprotective in Parkinson's disease?
    Gerlach M; Youdim MB; Riederer P
    J Neural Transm Suppl; 1994; 41():177-88. PubMed ID: 7931225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS; Fazzini E; Volkow ND
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract]   [Full Text] [Related]  

  • 11. Parkinson's disease: current view.
    Langston JW
    Am Fam Physician; 1987 Mar; 35(3):201-6. PubMed ID: 3103408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
    Cohen G
    J Neural Transm Suppl; 1983; 19():89-103. PubMed ID: 6321651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M
    J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
    Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
    Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAO type B inhibitors as adjunct to L-dopa therapy.
    Youdim MB; Finberg JP
    Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moderate Parkinson's disease. Strategies for maximizing treatment.
    Silverstein PM
    Postgrad Med; 1996 Jan; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Parkinson's disease. From theory to practice.
    Ahlskog JE
    Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies.
    Riederer P; Youdim MB; Birkmayer W; Jellinger K
    Adv Biochem Psychopharmacol; 1978; 19():377-82. PubMed ID: 696465
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.